Cognitive Deficits in Anti-LGI1 Encephalitis Are Linked to Immunotherapy-Resistant White Matter Network Changes
Although traditionally viewed as a form of limbic encephalitis, our study characterizes LGI1-E as a "network disorder" that affects the whole brain. Structural reorganization of WM networks was linked to long-term and multidomain cognitive impairment, which was not prevented by immunotherapy. These findings highlight the need for closer monitoring and improved treatment strategies to mitigate long-term cognitive impairment in LGI1-E.
Authors
- Leonie Müller‐Jensen (ORCID: https://orcid.org/0000-0002-6388-9375)
- Sophia Rekers (ORCID: https://orcid.org/0000-0002-6161-6621)
- Frank Leypoldt (ORCID: https://orcid.org/0000-0002-8972-515X)
- Christoph J. Ploner (ORCID: https://orcid.org/0000-0003-0983-4530)
- Harald Prüß (ORCID: https://orcid.org/0000-0002-8283-7976)
- Stephan Krohn (ORCID: https://orcid.org/0000-0003-0683-5386)
- Friedemann Paul (ORCID: https://orcid.org/0000-0002-6378-0070)
- Thorsten Bartsch (ORCID: https://orcid.org/0000-0001-8387-5731)
- Katharina Wurdack (ORCID: https://orcid.org/0000-0003-0952-5658)
- Joseph Kuchling (ORCID: https://orcid.org/0000-0002-7981-2073)
- Amy Romanello (ORCID: https://orcid.org/0000-0003-1257-9593)
- Carsten Finke (ORCID: https://orcid.org/0000-0002-7665-1171)
Institutions
- Max Delbrück Center (DE)
- German Center for Neurodegenerative Diseases (DE)
- University Medical Center (US)
- Christian-Albrechts-Universität zu Kiel (DE)
- Humboldt-Universität zu Berlin (DE)
- University Hospital and Clinics (US)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Neurology Neuroimmunology & Neuroinflammation
- Published
- 2025-01-29
- DOI
- https://doi.org/10.1212/nxi.0000000000200360
- Citations
- 9
- Primary Topic
- Autoimmune Neurological Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 12.50
Funders
- Pfizer
- GlaxoSmithKline
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Alexion Pharmaceuticals
- Celgene
- E-Rare
- University of Oxford
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
- Else Kröner-Fresenius-Stiftung
- Eisai
- Neuraxpharm
- Grifols
- Berlin Institute of Health
- Sanofi Genzyme